SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials

/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL...

Related Keywords

Ireland ,Australia ,Japan ,United States ,Dublin ,Piedmont ,New South Wales ,Canada ,Chicago ,Illinois ,American ,Jason Weidman ,Medtronic Symplicity Spyral ,Symplicity Spyral ,David Kandzari ,Coll Cardiol ,Prnewswire Medtronic ,Ryan Weispfenning ,Krystin Hayward Leong ,American Heart Association ,Linkedin ,Piedmont Heart Institute ,Cardiovascular Services ,Drug Administration ,Exchange Commission ,Public Health ,Medtronic ,Our Mission ,Late Breaking Clinical Science ,Scientific Sessions ,Premarket Approval ,Medtronic Symplicity Spyral Renal Denervation ,Win Ratio ,Renal Denervation ,Cardiovascular Portfolio ,Renal Denervation Investors ,Analyst Briefing ,Medtronic Coronary ,Investor Events ,